Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving. The company offers Xtampza, an abuse-deterrent, extended-release, oral formulation of oxycodone for opioid medication. It is also developing Onsolis, a transmucosal immediate-release fentanyl film indicated for the management of breakthrough pain in cancer patients 18 years of age and older. In addition, the company offers Nucynta ER, an extended release formulation of tapentadol for the management of pain severe enough to require daily, around-the-clock, long term opioid treatment, such as neuropathic pain related to diabetic peripheral neuropathy in adults; and Nucynta IR, an immediate release formulation of tapentadol that is indicated for the management of moderate to severe acute pain in adults. Further, it is developing COL-195, an abuse-deterrent, extended-release hydrocodone for the treatment of chronic pain; COL-172, an abuse-deterrent, extended-release oxymorphone for the treatment of chronic pain; and COL-171, a proprietary preclinical DETERx extended-release, abuse-deterrent methylphenidate formulation for attention deficit hyperactivity disorder (ADHD), as well as COL-196, a morphine formulation. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Canton, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:COLL
CUSIPN/A
Phone781-713-3699
Debt
Debt-to-Equity Ratio3.91
Current Ratio0.83
Quick Ratio0.80
Price-To-Earnings
Trailing P/E Ratio-8.25
Forward P/E Ratio-14.56
P/E GrowthN/A
Sales & Book Value
Annual Sales$28.48 million
Price / Sales23.65
Cash FlowN/A
Price / CashN/A
Book Value$3.20 per share
Price / Book6.37
Profitability
EPS (Most Recent Fiscal Year)($2.47)
Net Income$-74,860,000.00
Net Margins-78.22%
Return on Equity-72.87%
Return on Assets-26.11%
Miscellaneous
Employees250
Outstanding Shares33,040,000
Market Cap$665.84
Collegium Pharmaceutical (NASDAQ:COLL) Frequently Asked Questions
What is Collegium Pharmaceutical's stock symbol?
Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL."
How were Collegium Pharmaceutical's earnings last quarter?
Collegium Pharmaceutical Inc (NASDAQ:COLL) announced its earnings results on Wednesday, May, 9th. The specialty pharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.55) by $0.02. The specialty pharmaceutical company earned $63.70 million during the quarter, compared to analyst estimates of $51.92 million. Collegium Pharmaceutical had a negative net margin of 78.22% and a negative return on equity of 72.87%. The firm's quarterly revenue was up 2835.5% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.79) EPS. View Collegium Pharmaceutical's Earnings History.
When is Collegium Pharmaceutical's next earnings date?
What price target have analysts set for COLL?
7 equities research analysts have issued 12-month price targets for Collegium Pharmaceutical's shares. Their forecasts range from $26.00 to $40.00. On average, they anticipate Collegium Pharmaceutical's share price to reach $33.3333 in the next twelve months. This suggests a possible upside of 65.4% from the stock's current price. View Analyst Ratings for Collegium Pharmaceutical.
What is the consensus analysts' recommendation for Collegium Pharmaceutical?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Collegium Pharmaceutical in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
What are Wall Street analysts saying about Collegium Pharmaceutical stock?
Here are some recent quotes from research analysts about Collegium Pharmaceutical stock:
- 1. According to Zacks Investment Research, "Collegium Pharmaceutical Inc. is a specialty pharmaceutical company. It develops and commercializes prescription and over-the-counter pharmaceuticals for the treatment of central nervous system, respiratory and skin related disorders. The Company's product candidate consists of COL-195, COL-196, COL-171, COL-003 and COL-172 which are in different clinical trial. It developed a formulation platform technology, DETERx, for the treatment of chronic pain. Collegium Pharmaceutical Inc. is based in CUMBERLAND, United States. " (7/10/2018)
- 2. Cantor Fitzgerald analysts commented, "Collegium’s lead growth driver is Xtampza, which we believe could replace OxyContin as the largest branded oxycodone ER product. We expect upwards earnings revisions to levels not reflected in FactSet consensus to drive COLL shares higher. Valuation Summary We use a blend of DCF and EV/EBITDA to arrive at our $40 price target. The Disclosure Section may be found on pages 3 – 4.Valuation We use a blend of DCF and EV/EBITDA to arrive at our $40 price target." (6/20/2018)
Who are some of Collegium Pharmaceutical's key competitors?
Some companies that are related to Collegium Pharmaceutical include Akcea Therapeutics (AKCA), Portola Pharmaceuticals (PTLA), Clovis Oncology (CLVS), Endo International (ENDP), Spectrum Pharmaceuticals (SPPI), Enanta Pharmaceuticals (ENTA), Xencor (XNCR), Akorn (AKRX), Arena Pharmaceuticals (ARNA), TESARO (TSRO), Global Blood Therapeutics (GBT), ACADIA Pharmaceuticals (ACAD), Zogenix (ZGNX), Myokardia (MYOK) and Puma Biotechnology (PBYI).
Who are Collegium Pharmaceutical's key executives?
Collegium Pharmaceutical's management team includes the folowing people:
- Mr. Michael T. Heffernan, Co-Founder, Chairman & Pres (Age 54)
- Mr. Paul J. Brannelly, Exec. VP & CFO (Age 45)
- Mr. Joseph J. Ciaffoni, Exec. VP & COO (Age 47)
- Dr. Alison B. Fleming, Exec. VP & Chief Technology Officer (Age 43)
- Ms. Shirley R. Kuhlmann, Exec. VP, Gen. Counsel & Sec. (Age 34)
When did Collegium Pharmaceutical IPO?
(COLL) raised $75 million in an initial public offering on Thursday, May 7th 2015. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.
Has Collegium Pharmaceutical been receiving favorable news coverage?
News coverage about COLL stock has been trending somewhat positive on Monday, Accern Sentiment reports. Accern identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Collegium Pharmaceutical earned a media sentiment score of 0.22 on Accern's scale. They also assigned headlines about the specialty pharmaceutical company an impact score of 46.22 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
Who are Collegium Pharmaceutical's major shareholders?
Collegium Pharmaceutical's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Fisher Asset Management LLC (0.15%) and Atria Investments LLC (0.03%). Company insiders that own Collegium Pharmaceutical stock include Alison B Fleming, John A Fallon, Joseph Ciaffoni, Longitude Capital Partners, Ll, Michael Thomas Heffernan and Paul Brannelly. View Institutional Ownership Trends for Collegium Pharmaceutical.
Which institutional investors are selling Collegium Pharmaceutical stock?
COLL stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC. Company insiders that have sold Collegium Pharmaceutical company stock in the last year include Alison B Fleming, Joseph Ciaffoni, Longitude Capital Partners, Ll, Michael Thomas Heffernan and Paul Brannelly. View Insider Buying and Selling for Collegium Pharmaceutical.
Which institutional investors are buying Collegium Pharmaceutical stock?
COLL stock was acquired by a variety of institutional investors in the last quarter, including Atria Investments LLC. Company insiders that have bought Collegium Pharmaceutical stock in the last two years include John A Fallon and Paul Brannelly. View Insider Buying and Selling for Collegium Pharmaceutical.
How do I buy shares of Collegium Pharmaceutical?
Shares of COLL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Collegium Pharmaceutical's stock price today?
One share of COLL stock can currently be purchased for approximately $20.15.
How big of a company is Collegium Pharmaceutical?
Collegium Pharmaceutical has a market capitalization of $665.84 million and generates $28.48 million in revenue each year. The specialty pharmaceutical company earns $-74,860,000.00 in net income (profit) each year or ($2.47) on an earnings per share basis. Collegium Pharmaceutical employs 250 workers across the globe.
How can I contact Collegium Pharmaceutical?
Collegium Pharmaceutical's mailing address is 780 DEDHAM STREET SUITE 800, CANTON MA, 02021. The specialty pharmaceutical company can be reached via phone at 781-713-3699.
MarketBeat Community Rating for Collegium Pharmaceutical (NASDAQ COLL)
MarketBeat's community ratings are surveys of what our community members think about Collegium Pharmaceutical and other stocks. Vote "Outperform" if you believe COLL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe COLL will underperform the S&P 500 over the long term. You may vote once every thirty days.
